Skip to main content
SpringerLink
Log in

LRRK2 Is Associated with Recurrence-Free Survival in Intrahepatic Cholangiocarcinoma and Downregulation of LRRK2 Suppresses Tumor Progress In Vitro

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

The leucine-rich repeat kinase 2 (LRRK2) gene was confirmed to be associated with a variety of diseases, while the physiological function of LRRK2 remains poorly understood. Intrahepatic cholangiocarcinoma (ICC) has over the last 10 years become the focus of increasing concern largely. Despite recent progress in the standard of care and management options for ICC, the prognosis for this devastating cancer remains dismal.

Methods

A total of 57 consecutive ICC patients who underwent curative hepatectomy in our institution were included in our study. We conduct a retrospective study to evaluate the prognostic value of LRRK2 in ICC after resection. The mechanism of LRRK2 in ICC development was also investigated in vitro.

Results

All patients were divided into two groups according to the content of LRRK2 in the tissue microarray blocks via immunohistochemistry: low-LRRK2 group (n = 33) and high-LRRK2 group (n = 24). The recurrence-free survival rate of high-LRRK2 group was significantly poorer than that of low-LRRK2 group (P = 0.010). Multivariate analysis showed high-LRRK2 was the prognostic factor for recurrence-free survival after hepatectomy. We demonstrated that downregulation of LRRK2 depressed the proliferation and metastasis of ICC cells in vitro.

Conclusion

We provide evidence that LRRK2 was an independent prognostic factor for ICC in humans by participating in the proliferation and metastasis of ICC cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Maithel SK, Gamblin TC, Kamel I, Corona-Villalobos CP, Thomas M, Pawlik TM. Multidisciplinary approaches to intrahepatic cholangiocarcinoma. Cancer. 2013;119:3929–3942.

    Article  Google Scholar 

  2. Sirica AE, Gores GJ, Groopman JD, et al. Intrahepatic cholangiocarcinoma: continuing challenges and translational advances. Hepatology. 2018;69(4):1803–1815.

    Article  Google Scholar 

  3. Zhang CH, Xu H, Zhou ZP, et al. Blocking of the EGFR-STAT3 signaling pathway through afatinib treatment inhibited the intrahepatic cholangiocarcinoma. Exp Ther Med. 2018;15:4995–5000.

    PubMed  PubMed Central  Google Scholar 

  4. Patel T. New insights into the molecular pathogenesis of intrahepatic cholangiocarcinoma. J Gastroenterol. 2014;49:165–172.

    Article  CAS  Google Scholar 

  5. Nakanuma Y, Harada K, Ishikawa A, Zen Y, Sasaki M. Anatomic and molecular pathology of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2003;10:265–281.

    Article  Google Scholar 

  6. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology. Neuron. 2004;44:601–607.

    Article  CAS  Google Scholar 

  7. Cookson MR. LRRK2 pathways leading to neurodegeneration. Curr Neurol Neurosci. 2015;15:42.

    Article  Google Scholar 

  8. Moehle MS, Webber PJ, Tse T, et al. LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci. 2012;32:1602–1611.

    Article  CAS  Google Scholar 

  9. Schapansky J, Nardozzi JD, LaVoie MJ. The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson’s disease. Neuroscience. 2015;302:74–88.

    Article  CAS  Google Scholar 

  10. Inzelberg R, Cohen OS, Aharon-Peretz J, et al. The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers. Neurology. 2012;78:781–786.

    Article  CAS  Google Scholar 

  11. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet. 2008;40:955–962.

    Article  CAS  Google Scholar 

  12. Looyenga BD, Furge KA, Dykema KJ, et al. Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. Proc Natl Acad Sci USA. 2011;108:1439–1444.

    Article  Google Scholar 

  13. Waro BJ, Aasly JO. Exploring cancer in LRRK2 mutation carriers and idiopathic Parkinson’s disease. Brain Behav. 2018;8:e00858.

    Article  Google Scholar 

  14. Sierra M, Martinez-Rodriguez I, Sanchez-Juan P, et al. Prospective clinical and DaT-SPECT imaging in premotor LRRK2 G2019S-associated Parkinson disease. Neurology. 2017;89:439–444.

    Article  CAS  Google Scholar 

  15. Vilas D, Ispierto L, Alvarez R, et al. Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers. Parkinsonism Relat Disord. 2015;21:1170–1176.

    Article  Google Scholar 

  16. Park HJ, Jang KM, Kang TW, et al. Identification of imaging predictors discriminating different primary liver tumours in patients with chronic liver disease on Gadoxetic acid-enhanced MRI: a classification tree analysis. Eur Radiol. 2016;26:3102–3111.

    Article  Google Scholar 

  17. Tsunematsu S, Chuma M, Kamiyama T, et al. Intratumoral artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma. Abdom Imaging. 2015;40:1492–1499.

    Article  Google Scholar 

  18. Fujita N, Asayama Y, Nishie A, et al. Mass-forming intrahepatic cholangiocarcinoma: Enhancement patterns in the arterial phase of dynamic hepatic CT—correlation with clinicopathological findings. Eur Radiol. 2017;27:498–506.

    Article  Google Scholar 

  19. Wang C, Dai J, Sun Z, et al. Targeted inhibition of disheveled PDZ domain via NSC668036 depresses fibrotic process. Exp Cell Res. 2015;331:115–122.

    Article  CAS  Google Scholar 

  20. Zhu Y, Chen J, Kong WW, et al. Predicting IDH mutation status of intrahepatic cholangiocarcinomas based on contrast-enhanced CT features. Eur Radiol. 2018;28:159–169.

    Article  Google Scholar 

  21. Shuang Z, Mao Y, Lin G, et al. Alpha-L-fucosidase serves as a prognostic indicator for intrahepatic cholangiocarcinoma and inhibits its invasion capacity. Biomed Res Int. 2018;2018:8182575.

    Article  Google Scholar 

  22. Sirica AE. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;9:44–54.

    Article  Google Scholar 

  23. Thanee M, Loilome W, Techasen A, et al. Quantitative changes in tumor-associated M2 macrophages characterize cholangiocarcinoma and their association with metastasis. Asian Pac J Cancer Prev. 2015;16:3043–3050.

    Article  Google Scholar 

  24. Gardet A, Benita Y, Li C, et al. LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol. 2010;185:5577–5585.

    Article  CAS  Google Scholar 

  25. Pons B, Armengol G, Livingstone M, et al. Association between LRRK2 and 4E-BP1 protein levels in normal and malignant cells. Oncol Rep. 2012;27:225–231.

    CAS  PubMed  Google Scholar 

  26. Chan SL, Tan EK. Targeting LRRK2 in Parkinson’s disease: an update on recent developments. Expert Opin Ther Targets. 2017;21:601–610.

    Article  CAS  Google Scholar 

  27. Henderson JL, Kormos BL, Hayward MM, et al. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J Med Chem. 2015;58:419–432.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We thank Hui Zhao, Chuang Chen, Xiaopeng Yan, and Mingxuemei Jiang for assistance. The authors declare they have no competing interests. This work was supported by the National Natural Science Foundation of China (81470866) and the Key Medical Subjects of Jiangsu Province (ZDRCA2016057).

Author information

Authors and Affiliations

  1. Department of Hepatopancreatobiliary Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China

    Shen Gu & Yudong Qiu

  2. Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China

    Jun Chen

  3. Immunology and Reproduction Biology Laboratory & State Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, 210093, Jiangsu, China

    Shen Gu, Minghao Yan & Xiaodong Han

  4. Jiangsu Key Laboratory of Molecular Medicine, Nanjing University, Nanjing, 210093, Jiangsu, China

    Shen Gu, Minghao Yan & Xiaodong Han

  5. Department of Radiology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China

    Qun Zhou & Jian He

Authors
  1. Shen Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jun Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qun Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Minghao Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jian He
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiaodong Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yudong Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yudong Qiu.

Ethics declarations

Conflict of interest

Shen Gu, Jun Chen, Minghao Yan, Qun Zhou, Jian He, Yudong Qiu, Xiaodong Han declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 1296 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gu, S., Chen, J., Zhou, Q. et al. LRRK2 Is Associated with Recurrence-Free Survival in Intrahepatic Cholangiocarcinoma and Downregulation of LRRK2 Suppresses Tumor Progress In Vitro. Dig Dis Sci 65, 500–508 (2020). https://doi.org/10.1007/s10620-019-05806-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-019-05806-0

Keywords

Search

Navigation